The mutations were frequent in both MSI-H GC (15.5%) and CRC (5.5%); NLRP9 mutations revealed ITH; and NLRP9 expression was frequently lost in NLRP9-mutated cancers. This evidence concerns the gene NLRP9 and cancer.